AnaptysBio, Inc.

As of March 31, 2026, AnaptysBio, Inc. carries a market capitalization of 1.40B, placing it among publicly traded companies globally. Its enterprise value stands at 1.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, AnaptysBio, Inc. has 29.03M shares outstanding.

These figures are as of March 31, 2026. The price-to-sales ratio is 6.78, and the price-to-book ratio stands at 126.89.

As of March 31, 2026, AnaptysBio, Inc. trades at an EV/EBITDA multiple of 31.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.79 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 32.96 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.16B versus a market cap of 1.40B, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, AnaptysBio, Inc. maintains a current ratio of 7.58, meaning it holds 7.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 106.79, indicating elevated leverage, while an interest coverage ratio of 0.52 demonstrates limited ability to service its debt obligations.

Over the twelve months ended March 31, 2026, AnaptysBio, Inc. posted a negative return on equity (ROE) of -114.55, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -7.13, reflecting losses generated across the asset base. The company generates approximately 1.68M in revenue per employee across its workforce of 120.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended March 31, 2026, AnaptysBio, Inc. recorded 138,416.00 in income tax expense. The company reported a pretax loss of -23.04M and -23.17M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, AnaptysBio, Inc.'s stock has gained approximately 46.90% over the past 52 weeks. The 50-day moving average sits at 46.14, while the 200-day moving average is 48.83.

Over the twelve months ended March 31, 2026, AnaptysBio, Inc. generated 201.04M in revenue and converted that into -23.17M in net income, yielding earnings per share of -0.79. EBITDA reached 37.39M, while operating income came in at 35.29M.

As of March 31, 2026, AnaptysBio, Inc. holds 247.81M in cash and equivalents against 11.78M in total debt, resulting in a net debt position of -214.95M. Total book value stands at 11.03M, with working capital of 237.39M providing operational flexibility.

AnaptysBio, Inc. produced 3.87M in operating cash flow over the twelve months ended March 31, 2026. After subtracting -59,691.90 in capital expenditures, free cash flow totaled 3.81M - equivalent to 0.13 per share.

These figures cover the twelve months ended March 31, 2026. The operating margin of 17.56 and net profit margin of -11.53 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield stands at 0.27, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 6.36, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to AnaptysBio, Inc. shareholders.

As of March 31, 2026, AnaptysBio, Inc. has an Altman Z-Score of 1.67, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.